PMID- 12165862
OWN - NLM
STAT- MEDLINE
DCOM- 20020919
LR  - 20211008
IS  - 0950-9232 (Print)
IS  - 0950-9232 (Linking)
VI  - 21
IP  - 36
DP  - 2002 Aug 15
TI  - Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical 
      cancer.
PG  - 5631-42
AB  - Previous molecular genetic studies on HeLa cell (a cervical cancer cell line) 
      derived non-tumorigenic and tumorigenic hybrids have localized a tumor suppressor 
      gene to the long arm of chromosome 11. Analysis of cervical cancer cell lines 
      using chromosome 11 specific probes showed deletion and translocation of 11q13 
      sequences in five out of eight cell lines. Fluorescence in situ hybridization 
      (FISH), using 11q13 specific probes, has shown interstitial deletion of 11q13 
      sequences in the HeLa cells. In order to determine whether 11q13 deletions occur 
      in primary cervical tumors, we analysed 36 tumors using 20 different 
      microsatellite and RFLP markers. Semi automated fluorescein based allelotyping 
      was performed to identify loss of heterozygosity (LOH) in tumors. The results 
      showed allelic loss in 17 (47%) tumors. Three different regions of loss, one near 
      MEN1, the second near D11S913, and the third near INT2 locus were observed. The 
      smallest region of deletion overlap at the D11S913 locus was localized to a 300 
      Kb distance between D11S4908 and D11S5023. Fluorescence in situ hybridization 
      (FISH), using 11q13 specific cosmid and BAC (bacterial artificial chromosome) 
      probes, confirmed allelic deletion in the tumors. PCR analysis further identified 
      homozygous deletion of 11q13 sequences in a primary tumor, in HeLa cells and in 
      two HeLa cell derived tumorigenic hybrid cell lines. The homozygous deletion in 
      the cell lines was mapped to a 5.7 kb sequence of 11q13. We hypothesize therefore 
      that a putative cervical cancer tumor suppressor gene exists within the 300 kb of 
      chromosome 11q13.
FAU - Srivatsan, Eri S
AU  - Srivatsan ES
AD  - Department of Surgery, VAGLAHS West Los Angeles, UCLA School of Medicine, Los 
      Angeles, California, CA 90073, USA. esrivats@ucla.edu
FAU - Chakrabarti, Rita
AU  - Chakrabarti R
FAU - Zainabadi, Kayvan
AU  - Zainabadi K
FAU - Pack, Svetlana D
AU  - Pack SD
FAU - Benyamini, Payam
AU  - Benyamini P
FAU - Mendonca, Marc S
AU  - Mendonca MS
FAU - Yang, Pok Kwan
AU  - Yang PK
FAU - Kang, Kevin
AU  - Kang K
FAU - Motamedi, Daria
AU  - Motamedi D
FAU - Sawicki, Mark P
AU  - Sawicki MP
FAU - Zhuang, Zhengping
AU  - Zhuang Z
FAU - Jesudasan, Rachel A
AU  - Jesudasan RA
FAU - Bengtsson, Ulla
AU  - Bengtsson U
FAU - Sun, Chi
AU  - Sun C
FAU - Roe, Bruce A
AU  - Roe BA
FAU - Stanbridge, Eric J
AU  - Stanbridge EJ
FAU - Wilczynski, Sharon P
AU  - Wilczynski SP
FAU - Redpath, J Leslie
AU  - Redpath JL
LA  - eng
GR  - CA19401/CA/NCI NIH HHS/United States
GR  - CA39312/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Oncogene
JT  - Oncogene
JID - 8711562
RN  - 0 (DNA Primers)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (MEN1 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Proto-Oncogene Proteins)
SB  - IM
MH  - Centromere/genetics
MH  - *Chromosome Deletion
MH  - Chromosome Mapping
MH  - Chromosomes, Artificial, Bacterial/genetics/metabolism
MH  - Chromosomes, Human, Pair 11/*genetics
MH  - DNA Primers/chemistry
MH  - DNA, Neoplasm/*analysis
MH  - Endometrium/pathology
MH  - Female
MH  - *Genes, Tumor Suppressor
MH  - HeLa Cells
MH  - Humans
MH  - Hybrid Cells
MH  - Image Processing, Computer-Assisted
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Loss of Heterozygosity
MH  - Metaphase
MH  - Microsatellite Repeats
MH  - Neoplasm Proteins/genetics
MH  - Polymorphism, Single-Stranded Conformational
MH  - *Proto-Oncogene Proteins
MH  - Uterine Cervical Neoplasms/*genetics/pathology
EDAT- 2002/08/08 10:00
MHDA- 2002/09/20 10:01
CRDT- 2002/08/08 10:00
PHST- 2002/01/08 00:00 [received]
PHST- 2002/05/15 00:00 [revised]
PHST- 2002/05/20 00:00 [accepted]
PHST- 2002/08/08 10:00 [pubmed]
PHST- 2002/09/20 10:01 [medline]
PHST- 2002/08/08 10:00 [entrez]
AID - 10.1038/sj.onc.1205698 [doi]
PST - ppublish
SO  - Oncogene. 2002 Aug 15;21(36):5631-42. doi: 10.1038/sj.onc.1205698.